Kyverna Therapeutics (KYTX) Shares Outstanding (2023 - 2026)
Kyverna Therapeutics' (KYTX) quarterly Shares Outstanding (Entity) came in at $60.5 million in Q1 2026, up 40.06% YoY from $43.2 million in Q1 2025, and up 36.77% on a QoQ basis from $44.3 million in Q4 2025.
Kyverna Therapeutics (KYTX) Shares Outstanding (2023 - 2026) Analysis & Trends
Kyverna Therapeutics (KYTX) has 4 years of Shares Outstanding (Entity) data on file, last reported at $60.5 million in Q1 2026.
- Quarterly Shares Outstanding (Entity) rose 40.06% year-over-year to $60.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $60.5 million (up 40.06% YoY) and the FY2025 annual result came in at $44.3 million, up 2.42% from the prior year.
- Shares Outstanding (Entity) improved to $60.5 million in Q1 2026, from $44.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Entity) ranged from a high of $60.5 million in Q1 2026 to a low of $627589.0 in Q2 2023.
- A 4-year average of $30.1 million and a median of $43.2 million in 2024 frame the typical range for Shares Outstanding (Entity).
- Annual changes were most pronounced in 2024 — Shares Outstanding (Entity) surged 6775.02% — and 2025, when it rose 0.23%.
- Tracing KYTX's Shares Outstanding (Entity) over 4 years: stood at $673622.0 in 2023, then jumped by 6315.31% to $43.2 million in 2024, then advanced by 2.42% to $44.3 million in 2025, then surged by 36.77% to $60.5 million in 2026.
- The last three Shares Outstanding (Entity) figures came in at $60.5 million (Q1 2026), $44.3 million (Q4 2025), and $43.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Kyverna Therapeutics | 505.26 Mn | 505.26 Mn | - | 60.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 60.90 Mn |
| Mar 31, 2026 | 60.43 Mn |
| Dec 31, 2025 | 44.26 Mn |
| Sep 30, 2025 | 43.42 Mn |
| Jun 30, 2025 | 43.23 Mn |
| Mar 31, 2025 | 43.22 Mn |
| Dec 31, 2024 | 38.33 Mn |
| Sep 30, 2024 | 43.16 Mn |
| Jun 30, 2024 | 43.13 Mn |
| Mar 31, 2024 | 23.75 Mn |
| Dec 31, 2023 | 673,622.00 |
| Sep 30, 2023 | 664,656.00 |
| Jun 30, 2023 | 627,589.00 |
| Mar 31, 2023 | 921,260.00 |